Beverly L. Giammara
University of North Carolina at Chapel Hill
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Beverly L. Giammara.
MRS Proceedings | 1987
B. Mark Evers; Beverly L. Giammara; Denise Jubenville; Mark A. Malangoni
Coagulase-negative staphylococci are major pathogens in prosthetic implant infections, and the capability of certain strains to produce glycocalyx enhances their infectivity. We investigated the importance of glycocalyx in an animal model of prosthetic vascular graft infection. Coagulasenegative staphylococci (5×10 8 ) and 1 cm 2 pieces of Dacron or polytetrafluoroethylene (PTFE) grafts were placed in subcutaneous pockets of adult Sprague-Dawley rats. Two strains of bacteria were used, one producing and the other not producing glycocalyx. At 5 days, uninfected grafts were incorporated into the surrounding tissues whereas infected grafts were surrounded by fluid. Grafts were excised and adherent bacteria dislodged by sonication and quantitated. Scanning electron microscopy confirmed the presence of bacteria and glycocalyx, and the efficiency of bacterial dislodgement by sonication. The bacterial adherence (CFU/cm 2 mean ± SE) of glycocalyx-producing staphylococci was 3.7±1.1×10 7 and 3.5±1.0×10 5 to Dacron and PTFE, respectively (both 4 ) and PTFE (0.9±0.4±10 4 ). Antibiotic administration reduced the adherence of the nonglycocalyx producing strain by one log to both materials (p
Archive | 1984
Jacob S. Hanker; Peggy E. Yates; Wallace W. Ambrose; Joseph O. Moore; John Laszlo; William H. Starkweather; Beverly L. Giammara
Success in achieving remissions of acute myelogenous leukemia (AML) since the 1950s, and especially since the mid-1970s, has developed a need for greater attention on the part of physicians to improved methods for diagnosing and classifying the leukemias. The majority of AML patients can achieve first remissions, some (5–10%) lasting several years; these prolonged survivors are presumably cured of their leukemia. Many AML patients, however, are still not receiving the benefits of improved diagnostic methods and intensive therapeutic regimens. Of the latter group 80% are dead within a year of diagnosis [1].
Journal of Oral Pathology & Medicine | 1991
E. Jeff Burkes; Kenneth W. Lyles; Edward A. Dolan; Beverly L. Giammara; Jacob S. Hanker
Archive | 1984
Beverly L. Giammara; Jacob S. Hanker
MRS Online Proceedings Library Archive | 1985
Jacob S. Hanker; Myron R. Tucker; Bill C. Terry; Reynolds A. Carnevale; Beverly L. Giammara
Unknown Journal | 1993
Jacob S. Hanker; Dale N. Holdren; Kenneth L. Cohen; Beverly L. Giammara
Archive | 1989
Jacob S. Hanker; Beverly L. Giammara; E. J. Burkes; George W. Greco
Archive | 1989
Jacob S. Hanker; Beverly L. Giammara
MRS Proceedings | 1987
Jacob S. Hanker; Peggy E. Yates; Beverly L. Giammara; Charles E. Rawlings; Janice Ovelmen-Levitt; Nicholas G. Georgiade; Robert F. Wilkins
MRS Proceedings | 1987
Stephen A. Fredette; Jacob S. Hanker; Bill C. Terry; Beverly L. Giammara